From the clinics to the courts: The role evidence should play in litigating medical care

Journal of Health Politics, Policy and Law

Volumn 26, Issue 2, 2001, Pages 409-427

  Morreim, E H ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; COURT; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH CARE QUALITY; HEALTH INSURANCE; LAW SUIT; MEDICAL RESEARCH; NOTE; STANDARD; TREATMENT PLANNING;

EID: 0035045135     PISSN: 03616878     EISSN: None     Source Type: Journal    
DOI: 10.1215/03616878-26-2-409     Document Type: Note

References (65)

1. Judge-made law and judge-made insurance: Honoring the reasonable expectations of the insured
2. High-dose chemotherapy for breast cancer
3. Breast cancer procedure bogus
4. Rating the appropriateness of coronary angiography - Do practicing physicians agree with an expert panel and with each other?
5. Scientific versus commercial sources of influence on the prescribing behavior of physicians
6. Scans could allay health fears, or spark new ones
7. Where next with stem-cell-supported high-dose therapy for breast cancer?
8. How large employers are shaping the health care marketplace (first of two parts)
9. Medical practice a la mode
10. National roundtable on health care quality. The urgent need to improve health care quality
11. Comparing generalist and specialty care: Discrepancies, deficiencies, and excesses
12. Rationing resources while improving quality: How to get more for less
13. Court-ordered reimbursement for unproven medical technology: Circumventing technology assessment
14. The safety of newly approved medicines: Do recent market removals mean there is a problem?
15. Managed care organizations and patient injury: Rethinking liability
16. No price too high?
17. Health system deregulation: Some aspects of health care system reform need not be held hostage
18. High-dose chemotherapy and breast cancer
19. Judicial protection of managed care consumers: An empirical study of insurance coverage disputes
20. To be complete
21. Disease management: New wine in new bottles?
22. Inadequate outpatient medical therapy for patient with asthma admitted to two urban hospitals
23. A proposal for federal legislation to address health insurance coverage for experimental and investigational treatments
24. Medical insurance payments and patients involved in research
25. When an insurer calls your treatment experimental
26. After bezwoda
27. Infertility treatment: An argument for mandated coverage
28. Controlling health care costs by controlling technology: A private contractual approach
29. Women rejecting trials for testing a cancer therapy
30. Hope for sale: Business thrives on unproven care, leaving science behind
31. Use and overuse of angiography and revascularization for acute coronary syndromes
32. Rational health policy and the legal standard of care: A call for judicial deference to medical practice guidelines
33. Translating medical science into medical practice: Do we need a National Medical Standards Board?
34. Compliance with National Asthma Management guidelines and specialty care
35. High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer
36. Business vs. medical ethics: Conflicting standards for managed care
37. Not my health care
38. Redefining quality by reassigning responsibility
39. Moral justice and legal justice in managed care: The ascent of contributive justice
40. Medicine meets resource limits: Restructuring the legal standard of care
41. Playing doctor: Corporate medical practice and medical malpractice
42. Confusion in the courts: Managed care financial structures and their impact on medical care
43. Quality of life: Erosions and opportunities under managed care
44. Saving lives, spending money: Shepherding the role of technology
45. Why are physicians not prescribing diuretics more frequently in the management of hypertension?
46. Physician, measure thyself
47. Lawsuit puts spotlight on hospital discharge criteria
48. Medical innovation and the critical role of health technology assessment
49. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer
50. Hate those medicare denials? Try moving
51. Learning diagnostic restraint
52. Who should determine when health care is medically necessary?
53. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer
54. Raising the bar: The use of performance guarantees by the Pacific Business Group on health
55. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoieric stem-cell transplantation for metastatic breast cancer
56. Insurance coverage for experimental technologies
57. Variation in office-based quality: A claims-based profile of care provided to medicare patients with diabetes
58. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study
59. Centers for education and research in therapeutics